Biocon Settles with Janssen for Biosimilar Launch
By Rediff Money Desk, New Delhi Aug 29, 2024 10:19
Biocon Biologics has reached an agreement with Janssen to launch its biosimilar medication for autoimmune diseases in Europe, Canada, and Japan. The settlement clears the way for commercialization of Bmab 1200, a proposed biosimilar to Stelara.
![Biocon Settles with Janssen for Biosimilar Launch](https://im.rediff.com/money/2023/nov/24biocon-biologics.jpg)
Photograph: Kind courtesy Biocon Biologics/Facebook
New Delhi, Aug 29 (PTI) Biocon Biologics on Thursday said it has inked a pact with Janssen for launching a biosimilar medication for the treatment of autoimmune diseases in Europe, the United Kingdom, Canada, and Japan.
The company, a subsidiary of Biocon Ltd, has inked a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson. This agreement clears the way to commercialise its Bmab 1200, a proposed biosimilar to Stelara.
As per the terms of the settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan, the company said in a statement.
Regulatory filings in these markets are currently under review, it added.
Biocon Biologics had earlier announced a settlement agreement in the US for Bmab 1200 launch no later than February 22, 2025, once approved by the USFDA.
The US health regulator has accepted the company's Biologics License Application (BLA) for Bmab 1200 for review.
"This settlement agreement is the testament to our proven track record of science and innovation and is another key milestone in our journey to bring our biosimilar Bmab 1200 (bUstekinumab) to global markets," Biocon Biologics CEO & Managing Director Shreehas Tambe said.
Bmab 1200 will significantly strengthen the company's immunology franchise, enabling it to offer an affordable and effective treatment option for patients impacted by autoimmune diseases, he added.
Stelara (Ustekinumab) has been approved for the treatment of psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
Stelara had worldwide sales of USD 10.85 billion in 2023.
Shares of Biocon were trading 0.9 per cent up at Rs 360.10 apiece on the BSE.
The company, a subsidiary of Biocon Ltd, has inked a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson. This agreement clears the way to commercialise its Bmab 1200, a proposed biosimilar to Stelara.
As per the terms of the settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan, the company said in a statement.
Regulatory filings in these markets are currently under review, it added.
Biocon Biologics had earlier announced a settlement agreement in the US for Bmab 1200 launch no later than February 22, 2025, once approved by the USFDA.
The US health regulator has accepted the company's Biologics License Application (BLA) for Bmab 1200 for review.
"This settlement agreement is the testament to our proven track record of science and innovation and is another key milestone in our journey to bring our biosimilar Bmab 1200 (bUstekinumab) to global markets," Biocon Biologics CEO & Managing Director Shreehas Tambe said.
Bmab 1200 will significantly strengthen the company's immunology franchise, enabling it to offer an affordable and effective treatment option for patients impacted by autoimmune diseases, he added.
Stelara (Ustekinumab) has been approved for the treatment of psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
Stelara had worldwide sales of USD 10.85 billion in 2023.
Shares of Biocon were trading 0.9 per cent up at Rs 360.10 apiece on the BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 15.63 ( -4.17)
- 51716103
- Srestha Finvest
- 1.94 ( -1.02)
- 39556969
- Inventure Growth & S
- 2.47 ( -19.81)
- 31916723
- Genpharmasec Ltd
- 3.51 ( -4.88)
- 21009955
- GTL Infrastructure
- 2.68 ( -0.37)
- 16825789
MORE NEWS
![Kia India Sales...](https://im.rediff.com/80-80/money/2021/apr/28kia.jpg)
Kia India Sales Surge 17% in August, Led by...
Kia India reported a 17% year-on-year increase in wholesales for August, reaching...
![Dharavi NGOs Back...](https://im.rediff.com/80-80/money/2024/jan/01jan-dharavi.jpg)
Dharavi NGOs Back Redevelopment Survey, Oppose...
NGOs in Dharavi support the ongoing redevelopment survey, accusing non-locals of...
![Maruti Suzuki...](https://im.rediff.com/80-80/money/2023/jan/02maruti.jpg)
Maruti Suzuki Sales Dip 4% in August - 1,81,782...
Maruti Suzuki India reported a 4% decline in total sales in August, reaching 1,81,782...